Acushnet Holdings forecasts mid- to high single-digit EBITDA growth in Q2 2026 driven by key product launches—SM11 wedges, accelerated metals, and an early driver launch—with contributions inferred at the SKU level. While precise SKU-level EBITDA figures remain undisclosed, these launches significantly underpin Titleist Golf Equipment's profitability outlook.
Generated by Dafinchi AI. Source-grounded AI analysis, not investment advice.
Can you quantify the expected EBITDA contribution by product launch (SM11 wedges, metals launch, new driver) for Q2 2026 at the SKU level?
Analysis of Expected EBITDA Contribution by Product Launches for Q2 2026 at the SKU Level
Acushnet Holdings Corp. (Ticker: GOLF) has provided forward-looking commentary and some quantitative guidance related to its product launches in 2026, particularly the SM11 Vokey wedges, metals launch, and new driver. While specific SKU-level EBITDA contributions are not explicitly disclosed in the earnings transcript and filings for Q4 2025, we can infer and contextualize expectations from their remarks and financial outlook.
Product Launch Timing and Drivers of Growth:
Segment Performance and Product Cycles:
Financial Outlook Relevant to Q2:
Tariffs and Costs:
Capital Expenditures and Supply Chain Investment:
SM11 Wedges:
Metals Launch:
New Driver:
For Q2 2026, Acushnet expects a mid- to high single-digit year-over-year increase in adjusted EBITDA for the first half of the year, with Q2 heavily weighted due to the:
While exact SKU-level EBITDA figures are not provided, the incremental contribution from these launches can be inferred to compose the majority of this growth in the Titleist Golf Equipment segment’s adjusted EBITDA in Q2. The company’s supply chain investments, inventory build, and production capacity scale underpin this forecasted profitability improvement despite ongoing tariff headwinds.
Key relevant excerpts: 176582.
If you require quantitative SKU-level EBITDA in absolute dollar terms, such data is not disclosed and would typically require internal company segmentation details or guidance beyond what is publicly available at this time.
Disclaimer: The output generated by dafinchi.ai, a Large Language Model (LLM), may contain inaccuracies or "hallucinations." Users should independently verify the accuracy of any mathematical calculations, numerical data, and associated units, as well as the credibility of any sources cited. The developers and providers of dafinchi.ai cannot be held liable for any inaccuracies or decisions made based on the LLM's output.
Management details the strategic and operational implications of moving the GTS launch for 2026 from Q3 to Q2, emphasizing market impact and supply chain coordination.
Sources used
Research questionHow did management characterize the shift from a Q3 to Q2 GTS launch for 2026?
Answer outline
Marvell attributes near-term data center margin pressure to the expanding mix of custom silicon, with management emphasizing that revenue levels and product mix drive gross margins each quarter. While the Q3 headwind is primarily a mix effect, management expects margins to stabilize as the custom ramp accelerates in H2 and broad-based growth supports margin expansion into fiscal 2028.
Sources used
Research questionWhat did management say about Data center margin drivers from custom mix?
Answer outline
Investors should read management’s “2H acceleration” as a qualitative uptick in the second half versus the first half, supported by guidance for sequential back-half growth and a Helios ramp that becomes more impactful in Q4. The Q2 107% YoY growth establishes the first-half baseline, with Q3 and Q4 expected to exceed it through supply and product timing.
Sources used
Research questionHow should investors interpret management’s view that data center AI growth will “accelerate” in the second half versus the first half, given Q2’s 107% year-over-year growth and the Q3/Q4 guidance trajectory?
Answer outline
Western Digital outlines a dual-path outlook: LTA pricing remains contract-driven and predictable, particularly for nearline pricing, while offering upside in non-nearline contracts, and the exabyte growth trajectory remains robust at 25% plus, supported by 40TB ePMR ramp and upcoming HAMR and higher-capacity drives, with visibility extending through 2029–2031. Quarterly margins may vary due to LTA timing, but the long-term demand signal remains strong.
Sources used
Research questionWhat did management say about LTA pricing and exabyte growth outlook?
Answer outline
Pfizer's update highlights a $1.5 billion year-to-date non-COVID uplift driven by Eliquis alongside other products like NURTEC and Padcev, though the exact split isn’t quantified. Eliquis is projected to grow 20%–25% this year, while Padcev shows an initial acceleration that should moderate as la/mUC penetration matures, with upside potential from MIBC over time.
Sources used
Research questionWithin the $1.5 billion year-to-date increase in non-COVID revenue guidance, how much is due to Eliquis versus other products, and what is the updated Eliquis growth outlook? Also, with Padcev's expanded label, what is the expected growth path for that asset going forward?
Answer outline
Match Group's Q2 2026 earnings discussion centers on a consistent MAU-payer trend correlation, where payer declines run smaller than MAU declines and payer penetration rose year over year. Management notes MAU momentum drives direct revenue per MAU and payer trends over time, but warns quarterly movements can diverge due to product and monetization initiatives, while maintaining a positive long-term outlook and guidance for payer declines to ease in H2.
Sources used
Research questionWhat did management say about MAU and payer trend correlation?
Answer outline
IFF's Scent segment posted an 8% Q2 sales rise led by double-digit growth in Fragrance Ingredients and a resilient Consumer Fragrance line, even as Fine Fragrance faced Middle East volatility. The firm outlines a two-track H2: mid-single-digit growth for Fine Fragrance with a Q3 soft patch and a rebound in Q4, while Consumer Fragrance normalizes after a standout Q2, underpinned by an R&D-driven push into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery is advancing on multiple fronts, led by volume-driven growth, a re-energized R&D pipeline, and stable management of regional volatility. In 2H, Fine Fragrance should soften in Q3 and rebound in Q4, while Consumer Fragrance normalizes to a low single-digit pace, with 2027 R&D investments positioned to bolster long-term competitive strength.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
Management ties the Scent recovery to a significantly stronger R&D pipeline and execution, with Scent sales up 8% and EBITDA up 5% driven by volume gains and productivity. For 2H, Fine Fragrance is expected to be soft in Q3 but stronger in Q4, while Consumer Fragrance should normalize to low-single-digit growth; the 2027 plan emphasizes sustained R&D investment, perfumer-led innovation, and a shift toward higher-value natural ingredients.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF's Scent recovery is led by Fragrance Ingredients and volume gains, with Fine Fragrance expected to be softer in Q3 and rebound in Q4. The company emphasizes a rebuilt R&D pipeline and higher-value product shifts to support competitive positioning into 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF outlines a Scent recovery driven by a strengthened R&D pipeline, improved go-to-market execution, and a strategy to lift market share across Fine and Consumer Fragrance. The company anticipates a softer Q3 but a stronger Q4 for Fine Fragrance and a normalization to low single-digit growth for Consumer Fragrance in H2, supported by an 8-9% of sales R&D investment through 2027.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline
IFF Scent’s recovery hinges on a rebuilt R&D engine and market-share gains in Consumer Fragrance, with Fine Fragrance stabilizing amid Middle East volatility and Fragrance Ingredients normalization. In H2, Fine Fragrance is expected to soften in Q3 and strengthen in Q4, while Consumer Fragrance normalizes to low single-digit growth; management also emphasizes sustaining R&D investment around 8-9% of sales to support 2027 competitiveness.
Sources used
Research questionWhat are the drivers of Scent's recovery, how will Fine Fragrance and Consumer Fragrance evolve in the second half, and what is the plan for R&D to support 2027?
Answer outline